Nom du produit:1,1-Dimethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride

IUPAC Name:1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride

CAS:174784-36-2
Formule moléculaire:C11H16ClN
Pureté:95%
Numéro de catalogue:CM223349
Poids moléculaire:197.71

Unité d'emballage Stock disponible Prix($) Quantité
CM223349-1g in stock ƐȯŞƴ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:174784-36-2
Formule moléculaire:C11H16ClN
Point de fusion:-
Code SMILES:CC1(C)NCCC2=C1C=CC=C2.[H]Cl
Densité:
Numéro de catalogue:CM223349
Poids moléculaire:197.71
Point d'ébullition:
N° Mdl:MFCD23701883
Stockage:

Category Infos

Tetrahydroisoquinolines
Tetrahydroisoquinoline is an organic compound with the chemical formula C9H11N. It is classified as a secondary amine, obtained from isoquinoline by hydrogenation. The tetrahydroisoquinoline moiety forms the backbone of several natural, synthetic and semi-synthetic drugs approved for the treatment of cancer, pain, gout and various neurodegenerative diseases.

Product Other Information

Product Overview 1,1-Dimethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride (DTQ) is a compound that belongs to the tetrahydroisoquinoline family.
Physical Properties 1,1-Dimethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride has poor solubility in water, which may limit its use in certain experiments.
Chemical Properties 1,1-Dimethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride is relatively easy to synthesize and purify.
Synthesis and Application 1,1-Dimethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride has been found to possess neuroprotective properties and has been studied for its potential use in the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's. 1,1-Dimethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride has also been found to have anti-inflammatory properties and has been studied for its potential use in the treatment of inflammatory diseases such as rheumatoid arthritis.
Future Directions One direction is to further investigate the neuroprotective properties of 1,1-Dimethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride and its potential use in the treatment of neurodegenerative diseases. Another direction is to investigate the anti-inflammatory properties of 1,1-Dimethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride and its potential use in the treatment of inflammatory diseases. Additionally, further studies are needed to investigate the pharmacokinetic properties of 1,1-Dimethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride and its potential use as a drug candidate. Finally, the development of new synthesis methods for 1,1-Dimethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride may lead to the discovery of new pharmacological properties and applications.